Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital

NEXT STORY
LIDDS announces a capital raise of a total of approximately SEK 59.3 million and accordingly secures long-term financing
PREV STORY
Sorrento Announces It Has Submitted an Emergency Use Authorization (EUA) Application for the COVI-TRACK Diagnostic Test for the Detection of Antibodies to SARS-CoV-2
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Vectura Group plc: 2017 Preliminary Results – Performance in-line with expectations, with strong in-market growth from key inhaled products

author_avatar
NASDAQ Market News

Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

author_avatar
NASDAQ Market News

Soricimed Publishes New Research Validating TRPV6 as a Therapeutic Target for Ovarian Cancer

MONCTON, New Brunswick, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Soricimed Biopharma Inc. ("Soricimed"), a ...

author_avatar
NASDAQ Market News